**Innovation Creates Opportunity**

**With The Life Sciences**

**The FDA Approval Process**

Global adaption of innovative treatments could drastically shrink the sales gap between conventional medicine and biotechnology.

- **Phase 0**: Exploring if and how a new drug may work
- **Phase 1**: Does the treatment work?
- **Phase 2**: Is the treatment better than conventional medicine?
- **Phase 3**: Does the treatment work for long-term effects
- **Phase 4**: Post-approval studies

**Current Trends in Biotech**

- **Global adaption of innovative treatments**
- **Conventional medicine**
- **Biotechnology**

**A Unique Challenge**

Introducing the MSCI Life Sciences Indexes

- **Viral infections**
- **Drug development**
- **Production**
- **FDA approval**
- **Clinical trials**
- **Treatment**
- **Mutation**

**Distribution of Sales Moves Closer Together**

- **2000**: $200B
- **2005**: $600B
- **2010**: $400B
- **2015**: $800B
- **2020**: $1T
- **2025**: $1.3T
- **2030**: $1.7T

**The FDA Approval Process**

- **IND submitted**
- **NDA/BLA submitted**
- **FDA approval**

**What’s the difference between conventional medicine and biotechnology?**

- **Conventional**
- **Biotech**

**Investment in Biotech**

- **Conventional**
- **Biotech**

**MSCI Life Sciences Indexes**

- **Biotechnology Conventional**
- **Protein & peptide therapeutics**
- **Monoclonal antibody**
- **Gene-modified cell therapy**
- **Other biotechnology product**
- **Oncology**
- **Is the treatment safe?**
- **Is the treatment better than conventional medicine?**
- **Does the treatment work for long-term effects?**
- **Post-approval studies**

**Biological Models**

- **Empirical screening**
- **Pharmacological screening**
- **Animal testing**
- **Human trials**
- **FDA approval**

**What is behind new treatments?**

- **Innovative company**
- **R&D**
- **FDA**
- **Clinical trials**
- **Distribution of sales**

**Learn more about the MSCI Life Sciences Indexes.**

**Investments in biotechnology**

- **ACWI**
- **IMI**
- **Oncology**
- **Immunology**
- **Protein & peptide therapeutics**
- **Monoclonal antibody**
- **Gene-modified cell therapy**
- **Other biotechnology product**

**MSCI Life Sciences Indexes**

- **MSCI Life Sciences Indexes**
- **MSCI EAFE Life Sciences Indexes**
- **MSCI All Country World Index (ACWI) Life Sciences Index**
- **MSCI All Country World Index (ACWI) Immunology Index**
- **MSCI All Country World Index (ACWI) Protein & peptide therapeutics Index**
- **MSCI All Country World Index (ACWI) Monoclonal antibody Index**
- **MSCI All Country World Index (ACWI) Gene-modified cell therapy Index**
- **MSCI All Country World Index (ACWI) Other biotechnology product Index**

**Distribution of Sales Moves Closer Together**

- **2021**: Record year for clinical trials

**Innovation and Opportunity**

- **Source**: Evaluate Pharma (2022)

**The FDA Approval Process**

- **Phase 0**: Exploring if and how a new drug may work
- **Phase 1**: Does the treatment work?
- **Phase 2**: Is the treatment better than conventional medicine?
- **Phase 3**: Does the treatment work for long-term effects
- **Phase 4**: Post-approval studies